Design, click synthesis, and biological evaluation of novel uracil-1,2,3-triazole hybrids as dual EGFR/CDK1 inhibitors: antiproliferative activity, mechanistic insights, and in silico studies
1.16% in control) in HT29 cells, accompanied by upregulation of Caspase-3 and BAX, with a rise in Bcl-2 whose significance remains to be established. Molecular docking predicted that 10a can occupy the ATP-binding pockets of both EGFR and CDK1, and normal-mode analysis (iMODS) suggested that the docked complexes are structurally plausible. Computational ADMET profiling, however, flags several liabilities for 10a, including predicted hepatotoxicity, low predicted oral absorption and a short predicted half-life. These findings highlight the uracil-triazole scaffold, specifically compound 10a, as a promising starting point for the development of targeted dual EGFR/CDK1 anticancer therapeutics.
Authors
- Ashraf A. Aly (ORCID: https://orcid.org/0000-0002-0314-3408)
- Elshimaa M. N. Abdelhafez (ORCID: https://orcid.org/0000-0002-0078-5261)
- Sageda A. Gedamy (ORCID: https://orcid.org/0009-0004-8910-9885)
- Aya Adel Fouly (ORCID: https://orcid.org/0000-0001-8397-7025)
- Alan B. Brown (ORCID: https://orcid.org/0000-0002-2669-5598)
- Asmaa H. Mohamed (ORCID: https://orcid.org/0000-0003-3635-6968)
Institutions
- Florida Institute of Technology (US)
- Minia University (EG)
Publication Details
- Journal
- RSC Advances
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1039/d6ra09088e
- Primary Topic
- Synthesis and Characterization of Heterocyclic Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Science and Technology Development Fund